Showing results (81-90 of 89) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 89 results.
Gynecologic Oncology Reports|February 2, 2018
Associated characteristics and impact on recurrence and survival of free-floating tumor fragments in the lumen of fallopian tubes in Type I and Type II endometrial cancerBenjamin B Albright, Jonathan D Black, Rachel Passarelli, et al.
Gynecologic and Obstetric Investigation|January 3, 2019
Ten-Year Comparison Study of Type 1 and 2 Endometrial Cancers: Risk Factors and OutcomesJacqueline Feinberg, Benjamin Albright, Jonathan Black, et al.
Gynecologic Oncology Reports|January 15, 2020
Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG Oncology study (NRG-GY008)Alessandro D Santin, Virginia Filiaci, Stefania Bellone, et al.
Journal of Cancer Research and Clinical Oncology|September 27, 2018
Impact of carboplatin hypersensitivity and desensitization on patients with recurrent ovarian cancerGary Altwerger, Esther B Florsheim, Gulden Menderes, et al.
Gynecologic Oncology Reports|May 7, 2026
Real World Outcomes of Pembrolizumab and Reduced-Dose Lenvatinib in Recurrent Endometrial Cancer by Platinum and p53 StatusAlexa Dzienny, Yasmin Abozenah, James Griffith, et al.
Gynecologic Oncology Reports|November 18, 2020
Prescribed medical cannabis in women with gynecologic malignancies: A single-institution survey-based studyEmily M Webster, Ghanshyam S Yadav, Stefan Gysler, et al.
Molecular Cancer Therapeutics|September 7, 2023
In Vivo and In Vitro Efficacy of Trastuzumab Deruxtecan in Uterine Serous CarcinomaLevent Mutlu, Diego D Manavella, Stefania Bellone, et al.
Oncogene|December 6, 2011
A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancerE S Ratner, F K Keane, R Lindner, et al.
Plos One|April 2, 2015
Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriersIgnacio Blanco, Karoline Kuchenbaecker, Daniel Cuadras, et al.
Pageof 9